Arunjyoti Bio Ventures Ltd (ABVL) fair value: what the stock is really worth
As of Oct 8, 2026: fair value of Arunjyoti Bio Ventures Ltd ₹6.32, price ₹4.67, upside +35.3%, quality 41 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range ₹0.0554 – ₹20.18 · fair‑value band ₹3.49 – ₹8.33 · the ₹4.67 price screens below the ₹6.32 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.
Follow Arunjyoti Bio Ventures in your weekly email
Every Wednesday you see whether Arunjyoti Bio Ventures is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Arunjyothi Bio Ventures Limited engages packing services in India. It serves carbonated and non-carbonated water beverage application products. Arunjyothi Bio Ventures Limited was formerly known as Century 21st Portfolio Limited and changed its name to Arunjyothi Bio Ventures Limited in 2014.
Show more
Arunjyothi Bio Ventures Limited engages packing services in India. It serves carbonated and non-carbonated water beverage application products. Arunjyothi Bio Ventures Limited was formerly known as Century 21st Portfolio Limited and changed its name to Arunjyothi Bio Ventures Limited in 2014. The company was incorporated in 1986 and is based in Hyderabad, India.
Stock analysis
Arunjyoti Bio Ventures Ltd (ABVL) currently trades at ₹4.67, while our model-based Fair Value estimate is ₹6.32, implying the stock looks roughly 26.1% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of ₹8.09 per share, and 6 of the 10 models we run sit above the ₹4.67 price.
Bear case: the Asset-Based group reads lowest at ₹1.03, and 4 of the 10 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹3.49 (bear) to ₹8.33 (bull), the price of ₹4.67 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Industrials sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Arunjyoti Bio Ventures Ltd reported revenue of ₹278M in FY2026 versus ₹29.7M in FY2022, a compound +74.8%/yr. Reported net income was −₹45.4M in FY2026.
Key figures
Market cap ₹870M (≈ $9.0M) · P/S ratio 2.74 · EPS (TTM) ₹−0.3200 · Net margin −16.3% · Return on equity −14.9% · Return on assets (EBIT) −1.0% · Operating margin 15.1% · Revenue (TTM) ₹272M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).
What moves the price
The share trades about 63% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Industrials peers we cover trades at 1% fair-value upside, at 35%, ABVL screens cheaper than that median.
Fair Value models
Bear ₹3.49Fair Value ₹6.32Bull ₹8.33
Price ₹4.67 · Upside +35.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.61/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−0.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+152.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.2%
Start year 2021 (pandemic)
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
1.7% (2021) → −1.0% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+9.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +5.2% a year for the price.
Compare Arunjyoti Bio Ventures Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Business Services · 231 stocks
Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score41 · Bottom 25%
Fair Value upside+35.3% · Above median
Profitability
Return on assets−0.5% · Bottom 25%
Net margin (TTM)−21.9% · Bottom 25%
Operating margin (TTM)15.1% · Top 25%
Growth and dividend
Revenue growth−5.9% · Bottom 25%
Balance sheet
Debt / equity0.40× · Above median
Valuation Multiplesvs Specialty Business Services median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Arunjyoti Bio Ventures Ltd Fair Value". https://www.fairvalue-calculator.com/stock/ABVL
Frequently asked questions
Is Arunjyoti Bio Ventures Ltd (ABVL) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of ₹6.32 versus a price of ₹4.67, about +35% upside (undervalued).
What is the fair value of ABVL?
Our model-based fair value for Arunjyoti Bio Ventures Ltd is ₹6.32 (as of Oct 3, 2026), built from audited fundamentals. The current price: ₹4.67.
What is the quality score of ABVL?
Arunjyoti Bio Ventures Ltd has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Arunjyoti Bio Ventures Ltd (ABVL)?
Our model-based price target is the fair value of ₹6.32 (as of Oct 3, 2026) from 10 valuation models. Cautious scenario ₹3.49, optimistic scenario ₹8.33. It is a calculation from audited fundamentals, not an analyst target.
What is the Arunjyoti Bio Ventures Ltd stock forecast for 2026?
Our models put fair value at ₹6.32, about +35% upside versus a price of ₹4.67 (undervalued). Cautious scenario ₹3.49, optimistic scenario ₹8.33. The calculation is refreshed regularly with new filings.
What is the revenue of Arunjyoti Bio Ventures Ltd (ABVL)?
Arunjyoti Bio Ventures Ltd reported trailing-twelve-month revenue of about ₹272M (latest available figure, as of Oct 3, 2026).
What growth is priced into Arunjyoti Bio Ventures Ltd (ABVL)?
For today's price to be fair in a discounted-cash-flow model, Arunjyoti Bio Ventures Ltd would have to grow free cash flow by +9.6 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +38.2 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of ABVL use?
Our models discount Arunjyoti Bio Ventures Ltd at 12.4 %: a base by market capitalisation (nano), country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Arunjyoti Bio Ventures Ltd that is +9.6 % per year a year over ten years, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has Arunjyoti Bio Ventures Ltd (ABVL) delivered so far?
Over the past 5 years revenue at Arunjyoti Bio Ventures Ltd grew +38.2 % a year. The price currently implies +9.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Arunjyoti Bio Ventures Ltd (ABVL) growing?
The median revenue growth in the sector is +7.4 % a year. That is the yardstick for the growth priced into Arunjyoti Bio Ventures Ltd (+9.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Arunjyoti Bio Ventures Ltd (ABVL)?
The free-cash-flow yield on the price is 8.56 %: that much free cash flow Arunjyoti Bio Ventures Ltd produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Arunjyoti Bio Ventures Ltd (ABVL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Arunjyoti Bio Ventures Ltd it is ₹6.32 per share (as of Oct 3, 2026), against a price of ₹4.67. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Arunjyoti Bio Ventures Ltd stock overvalued or undervalued in 2026?
As of Oct 3, 2026, ABVL trades below its calculated fair value: price ₹4.67, fair value ₹6.32, a gap of about +35% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ABVL?
No. The price is what the market pays today (₹4.67); the fair value is what the company's own numbers justify (₹6.32). For Arunjyoti Bio Ventures Ltd the two are ₹1.65 per share apart. That gap is exactly why we show both numbers side by side.
How much is Arunjyoti Bio Ventures Ltd worth?
The market values Arunjyoti Bio Ventures Ltd at about ₹870M (market capitalisation, as of Oct 3, 2026). Per share that is ₹4.67; our models calculate a fair value of ₹6.32 per share.
What do the bullish and bearish scenarios say about ABVL?
Our models span a range for Arunjyoti Bio Ventures Ltd: cautious scenario ₹3.49, base ₹6.32, optimistic ₹8.33 per share (as of Oct 3, 2026, price ₹4.67). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Arunjyoti Bio Ventures Ltd (ABVL)?
Balance-sheet figures for Arunjyoti Bio Ventures Ltd (as of Oct 3, 2026): return on equity −14.9%, debt of 0.40 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is ABVL from its 52-week high?
Arunjyoti Bio Ventures Ltd trades at ₹4.67, about 63% below its 52-week high of ₹12.71 and 19% above the low of ₹3.92 (as of Oct 8, 2026). Distance from the high says nothing about value: that is what the fair value of ₹6.32 is for.
Which stocks are comparable to Arunjyoti Bio Ventures Ltd?
From the same area (Industrials) we also value Cintas Corporation, Thomson Reuters Corporation, Copart, Inc, Global Payments Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Arunjyoti Bio Ventures Ltd stock attractive at the current price?
The data as of Oct 3, 2026: price ₹4.67, calculated fair value ₹6.32 (+35%), Quality Score 41/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ABVL calculated?
We run Arunjyoti Bio Ventures Ltd through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹6.32, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Arunjyoti Bio Ventures Ltd currently trades 26 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Arunjyoti Bio Ventures Ltd (ABVL)?
The closing price on Oct 8, 2026 was ₹4.67. Our model-based fair value is ₹6.32, about +35% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Arunjyoti Bio Ventures Ltd right now?
The large discount to fair value meets weak quality (41/100). That raises the risk this is a value trap rather than a bargain. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (₹3.49 to ₹8.33) leaves room in how you read the outcome.
Key figures of Arunjyoti Bio Ventures Ltd
How large is the market capitalisation of Arunjyoti Bio Ventures Ltd (ABVL)?
The market capitalisation of Arunjyoti Bio Ventures Ltd is ₹870M (≈ $9.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Arunjyoti Bio Ventures Ltd (ABVL)?
The price-to-sales ratio of Arunjyoti Bio Ventures Ltd is 2.74 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Arunjyoti Bio Ventures Ltd (ABVL)?
Earnings per share at Arunjyoti Bio Ventures Ltd are ₹−0.3200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Arunjyoti Bio Ventures Ltd (ABVL)?
The net margin of Arunjyoti Bio Ventures Ltd is −16.3% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Arunjyoti Bio Ventures Ltd (ABVL)?
The return on equity (ROE) of Arunjyoti Bio Ventures Ltd is −14.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Arunjyoti Bio Ventures Ltd (ABVL)?
On an EBIT basis the return on assets of Arunjyoti Bio Ventures Ltd is −1.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Arunjyoti Bio Ventures Ltd (ABVL)?
The operating margin of Arunjyoti Bio Ventures Ltd is 15.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Arunjyoti Bio Ventures Ltd (ABVL)?
Revenue at Arunjyoti Bio Ventures Ltd is growing −5.9% versus a year earlier (3y avg +152%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Arunjyoti Bio Ventures Ltd (ABVL)?
Earnings per share at Arunjyoti Bio Ventures Ltd are growing −76.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Arunjyoti Bio Ventures Ltd (ABVL) carry?
The net debt of Arunjyoti Bio Ventures Ltd is ₹216M (fiscal year 2026, ≈ 2.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Arunjyoti Bio Ventures Ltd in the live analysis
One click puts Arunjyoti Bio Ventures Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
